カテゴリ： Market Monitor Global, 世界, 医療/バイオ

がん診断用リキッドバイオプシーのグローバル市場展望 2023年-2029年：血液検査、尿検査、唾液検査

■ 英語タイトル：Liquid Biopsy For Cancer Diagnostics Market, Global Outlook and Forecast 2023-2029

調査会社Market Monitor Global社が発行したリサーチレポート（データ管理コード：MMG23DC12386）■ 発行会社/調査会社：Market Monitor Global
■ 商品コード：MMG23DC12386
■ 発行日：2023年12月（※2025年版があります。お問い合わせください。）
■ 調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
■ 産業分野：医療
■ ページ数：102
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,250 ⇒換算￥468,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD4,225 ⇒換算￥608,400見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）USD4,875 ⇒換算￥702,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Market Monitor Global社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[がん診断用リキッドバイオプシーのグローバル市場展望 2023年-2029年：血液検査、尿検査、唾液検査]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

当調査レポートは次の情報を含め、世界のがん診断用リキッドバイオプシー市場規模と予測を収録しています。・世界のがん診断用リキッドバイオプシー市場：売上、2018年-2023年、2024年-2029年
・世界のがん診断用リキッドバイオプシー市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界のがん診断用リキッドバイオプシー市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「血液検査」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

がん診断用リキッドバイオプシーのグローバル主要企業は、F. Hoffman La Roche Ltd.、 Thermo Fisher Scientific Inc.、 Agilent Technologies Inc.、 Illumina Inc.、 The Menarini Group、 Bio-Rad Laboratories Inc.、 QIAGEN Inc.、 Exact Sciences Corporation、 Bio-Techne Corporation、 ArcherDX Inc.、 Neogenomics Laboratories Inc.、 Guardant Health Inc.、 Myriad Genetics Inc.、 Foundation Medicine Inc.、 Amoy Diagnostics Co. Ltd.、 Biocartis Group NVなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、がん診断用リキッドバイオプシーのメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界のがん診断用リキッドバイオプシー市場：タイプ別、2018年-2023年、2024年-2029年
世界のがん診断用リキッドバイオプシー市場：タイプ別市場シェア、2022年
・血液検査、尿検査、唾液検査

世界のがん診断用リキッドバイオプシー市場：用途別、2018年-2023年、2024年-2029年
世界のがん診断用リキッドバイオプシー市場：用途別市場シェア、2022年
・病院、診断センター、その他

世界のがん診断用リキッドバイオプシー市場：地域・国別、2018年-2023年、2024年-2029年
世界のがん診断用リキッドバイオプシー市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業におけるがん診断用リキッドバイオプシーのグローバル売上、2018年-2023年
・主要企業におけるがん診断用リキッドバイオプシーのグローバル売上シェア、2022年
・主要企業におけるがん診断用リキッドバイオプシーのグローバル販売量、2018年-2023年
・主要企業におけるがん診断用リキッドバイオプシーのグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
F. Hoffman La Roche Ltd.、 Thermo Fisher Scientific Inc.、 Agilent Technologies Inc.、 Illumina Inc.、 The Menarini Group、 Bio-Rad Laboratories Inc.、 QIAGEN Inc.、 Exact Sciences Corporation、 Bio-Techne Corporation、 ArcherDX Inc.、 Neogenomics Laboratories Inc.、 Guardant Health Inc.、 Myriad Genetics Inc.、 Foundation Medicine Inc.、 Amoy Diagnostics Co. Ltd.、 Biocartis Group NV

*************************************************************

・調査・分析レポートの概要
がん診断用リキッドバイオプシー市場の定義
市場セグメント
世界のがん診断用リキッドバイオプシー市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界のがん診断用リキッドバイオプシー市場規模
世界のがん診断用リキッドバイオプシー市場規模：2022年 VS 2029年
世界のがん診断用リキッドバイオプシー市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでのがん診断用リキッドバイオプシーの売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業のがん診断用リキッドバイオプシー製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：血液検査、尿検査、唾液検査
がん診断用リキッドバイオプシーのタイプ別グローバル売上・予測

・用途別市場分析
用途区分：病院、診断センター、その他
がん診断用リキッドバイオプシーの用途別グローバル売上・予測

・地域別市場分析
地域別がん診断用リキッドバイオプシー市場規模 2022年と2029年
地域別がん診断用リキッドバイオプシー売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
F. Hoffman La Roche Ltd.、 Thermo Fisher Scientific Inc.、 Agilent Technologies Inc.、 Illumina Inc.、 The Menarini Group、 Bio-Rad Laboratories Inc.、 QIAGEN Inc.、 Exact Sciences Corporation、 Bio-Techne Corporation、 ArcherDX Inc.、 Neogenomics Laboratories Inc.、 Guardant Health Inc.、 Myriad Genetics Inc.、 Foundation Medicine Inc.、 Amoy Diagnostics Co. Ltd.、 Biocartis Group NV
...

This research report provides a comprehensive analysis of the Liquid Biopsy For Cancer Diagnostics market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Liquid Biopsy For Cancer Diagnostics market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Liquid Biopsy For Cancer Diagnostics, challenges faced by the industry, and potential opportunities for market players.
The global Liquid Biopsy For Cancer Diagnostics market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Liquid Biopsy For Cancer Diagnostics market presents opportunities for various stakeholders, including Hospital, Diagnostic Center. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Liquid Biopsy For Cancer Diagnostics market. Additionally, the growing consumer demand present avenues for market expansion.
The global Liquid Biopsy For Cancer Diagnostics market was valued at US$ 3398.9 million in 2022 and is projected to reach US$ 7703.3 million by 2029, at a CAGR of 13.1% during the forecast period.
Researchers and developers continue to explore and expand the clinical utility of liquid biopsy. This includes investigating its application in various cancer types, different stages of cancer, and for monitoring treatment response and minimal residual disease.
Key Features:
The research report on the Liquid Biopsy For Cancer Diagnostics market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Liquid Biopsy For Cancer Diagnostics market.
Market Overview: The report provides a comprehensive overview of the Liquid Biopsy For Cancer Diagnostics market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Blood Test, Urine Test), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Liquid Biopsy For Cancer Diagnostics market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Liquid Biopsy For Cancer Diagnostics market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Liquid Biopsy For Cancer Diagnostics market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Liquid Biopsy For Cancer Diagnostics market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Liquid Biopsy For Cancer Diagnostics market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Liquid Biopsy For Cancer Diagnostics market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Liquid Biopsy For Cancer Diagnostics, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Liquid Biopsy For Cancer Diagnostics market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Liquid Biopsy For Cancer Diagnostics market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Blood Test
Urine Test
Saliva Test
Market segment by Application
Hospital
Diagnostic Center
Others
Global Liquid Biopsy For Cancer Diagnostics Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
F. Hoffman La Roche Ltd.
Thermo Fisher Scientific Inc.
Agilent Technologies Inc.
Illumina Inc.
The Menarini Group
Bio-Rad Laboratories Inc.
QIAGEN Inc.
Exact Sciences Corporation
Bio-Techne Corporation
ArcherDX Inc.
Neogenomics Laboratories Inc.
Guardant Health Inc.
Myriad Genetics Inc.
Foundation Medicine Inc.
Amoy Diagnostics Co. Ltd.
Biocartis Group NV
Outline of Major Chapters:
Chapter 1: Introduces the definition of Liquid Biopsy For Cancer Diagnostics, market overview.
Chapter 2: Global Liquid Biopsy For Cancer Diagnostics market size in revenue.
Chapter 3: Detailed analysis of Liquid Biopsy For Cancer Diagnostics company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Liquid Biopsy For Cancer Diagnostics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

1 Introduction to Research & Analysis Reports
1.1 Liquid Biopsy For Cancer Diagnostics Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Liquid Biopsy For Cancer Diagnostics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Liquid Biopsy For Cancer Diagnostics Overall Market Size
2.1 Global Liquid Biopsy For Cancer Diagnostics Market Size: 2022 VS 2029
2.2 Global Liquid Biopsy For Cancer Diagnostics Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Liquid Biopsy For Cancer Diagnostics Players in Global Market
3.2 Top Global Liquid Biopsy For Cancer Diagnostics Companies Ranked by Revenue
3.3 Global Liquid Biopsy For Cancer Diagnostics Revenue by Companies
3.4 Top 3 and Top 5 Liquid Biopsy For Cancer Diagnostics Companies in Global Market, by Revenue in 2022
3.5 Global Companies Liquid Biopsy For Cancer Diagnostics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Liquid Biopsy For Cancer Diagnostics Players in Global Market
3.6.1 List of Global Tier 1 Liquid Biopsy For Cancer Diagnostics Companies
3.6.2 List of Global Tier 2 and Tier 3 Liquid Biopsy For Cancer Diagnostics Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Liquid Biopsy For Cancer Diagnostics Market Size Markets, 2022 & 2029
4.1.2 Blood Test
4.1.3 Urine Test
4.1.4 Saliva Test
4.2 By Type – Global Liquid Biopsy For Cancer Diagnostics Revenue & Forecasts
4.2.1 By Type – Global Liquid Biopsy For Cancer Diagnostics Revenue, 2018-2023
4.2.2 By Type – Global Liquid Biopsy For Cancer Diagnostics Revenue, 2024-2029
4.2.3 By Type – Global Liquid Biopsy For Cancer Diagnostics Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Liquid Biopsy For Cancer Diagnostics Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Diagnostic Center
5.1.4 Others
5.2 By Application – Global Liquid Biopsy For Cancer Diagnostics Revenue & Forecasts
5.2.1 By Application – Global Liquid Biopsy For Cancer Diagnostics Revenue, 2018-2023
5.2.2 By Application – Global Liquid Biopsy For Cancer Diagnostics Revenue, 2024-2029
5.2.3 By Application – Global Liquid Biopsy For Cancer Diagnostics Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Liquid Biopsy For Cancer Diagnostics Market Size, 2022 & 2029
6.2 By Region – Global Liquid Biopsy For Cancer Diagnostics Revenue & Forecasts
6.2.1 By Region – Global Liquid Biopsy For Cancer Diagnostics Revenue, 2018-2023
6.2.2 By Region – Global Liquid Biopsy For Cancer Diagnostics Revenue, 2024-2029
6.2.3 By Region – Global Liquid Biopsy For Cancer Diagnostics Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Liquid Biopsy For Cancer Diagnostics Revenue, 2018-2029
6.3.2 US Liquid Biopsy For Cancer Diagnostics Market Size, 2018-2029
6.3.3 Canada Liquid Biopsy For Cancer Diagnostics Market Size, 2018-2029
6.3.4 Mexico Liquid Biopsy For Cancer Diagnostics Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Liquid Biopsy For Cancer Diagnostics Revenue, 2018-2029
6.4.2 Germany Liquid Biopsy For Cancer Diagnostics Market Size, 2018-2029
6.4.3 France Liquid Biopsy For Cancer Diagnostics Market Size, 2018-2029
6.4.4 U.K. Liquid Biopsy For Cancer Diagnostics Market Size, 2018-2029
6.4.5 Italy Liquid Biopsy For Cancer Diagnostics Market Size, 2018-2029
6.4.6 Russia Liquid Biopsy For Cancer Diagnostics Market Size, 2018-2029
6.4.7 Nordic Countries Liquid Biopsy For Cancer Diagnostics Market Size, 2018-2029
6.4.8 Benelux Liquid Biopsy For Cancer Diagnostics Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Liquid Biopsy For Cancer Diagnostics Revenue, 2018-2029
6.5.2 China Liquid Biopsy For Cancer Diagnostics Market Size, 2018-2029
6.5.3 Japan Liquid Biopsy For Cancer Diagnostics Market Size, 2018-2029
6.5.4 South Korea Liquid Biopsy For Cancer Diagnostics Market Size, 2018-2029
6.5.5 Southeast Asia Liquid Biopsy For Cancer Diagnostics Market Size, 2018-2029
6.5.6 India Liquid Biopsy For Cancer Diagnostics Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Liquid Biopsy For Cancer Diagnostics Revenue, 2018-2029
6.6.2 Brazil Liquid Biopsy For Cancer Diagnostics Market Size, 2018-2029
6.6.3 Argentina Liquid Biopsy For Cancer Diagnostics Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Liquid Biopsy For Cancer Diagnostics Revenue, 2018-2029
6.7.2 Turkey Liquid Biopsy For Cancer Diagnostics Market Size, 2018-2029
6.7.3 Israel Liquid Biopsy For Cancer Diagnostics Market Size, 2018-2029
6.7.4 Saudi Arabia Liquid Biopsy For Cancer Diagnostics Market Size, 2018-2029
6.7.5 UAE Liquid Biopsy For Cancer Diagnostics Market Size, 2018-2029
7 Liquid Biopsy For Cancer Diagnostics Companies Profiles
7.1 F. Hoffman La Roche Ltd.
7.1.1 F. Hoffman La Roche Ltd. Company Summary
7.1.2 F. Hoffman La Roche Ltd. Business Overview
7.1.3 F. Hoffman La Roche Ltd. Liquid Biopsy For Cancer Diagnostics Major Product Offerings
7.1.4 F. Hoffman La Roche Ltd. Liquid Biopsy For Cancer Diagnostics Revenue in Global Market (2018-2023)
7.1.5 F. Hoffman La Roche Ltd. Key News & Latest Developments
7.2 Thermo Fisher Scientific Inc.
7.2.1 Thermo Fisher Scientific Inc. Company Summary
7.2.2 Thermo Fisher Scientific Inc. Business Overview
7.2.3 Thermo Fisher Scientific Inc. Liquid Biopsy For Cancer Diagnostics Major Product Offerings
7.2.4 Thermo Fisher Scientific Inc. Liquid Biopsy For Cancer Diagnostics Revenue in Global Market (2018-2023)
7.2.5 Thermo Fisher Scientific Inc. Key News & Latest Developments
7.3 Agilent Technologies Inc.
7.3.1 Agilent Technologies Inc. Company Summary
7.3.2 Agilent Technologies Inc. Business Overview
7.3.3 Agilent Technologies Inc. Liquid Biopsy For Cancer Diagnostics Major Product Offerings
7.3.4 Agilent Technologies Inc. Liquid Biopsy For Cancer Diagnostics Revenue in Global Market (2018-2023)
7.3.5 Agilent Technologies Inc. Key News & Latest Developments
7.4 Illumina Inc.
7.4.1 Illumina Inc. Company Summary
7.4.2 Illumina Inc. Business Overview
7.4.3 Illumina Inc. Liquid Biopsy For Cancer Diagnostics Major Product Offerings
7.4.4 Illumina Inc. Liquid Biopsy For Cancer Diagnostics Revenue in Global Market (2018-2023)
7.4.5 Illumina Inc. Key News & Latest Developments
7.5 The Menarini Group
7.5.1 The Menarini Group Company Summary
7.5.2 The Menarini Group Business Overview
7.5.3 The Menarini Group Liquid Biopsy For Cancer Diagnostics Major Product Offerings
7.5.4 The Menarini Group Liquid Biopsy For Cancer Diagnostics Revenue in Global Market (2018-2023)
7.5.5 The Menarini Group Key News & Latest Developments
7.6 Bio-Rad Laboratories Inc.
7.6.1 Bio-Rad Laboratories Inc. Company Summary
7.6.2 Bio-Rad Laboratories Inc. Business Overview
7.6.3 Bio-Rad Laboratories Inc. Liquid Biopsy For Cancer Diagnostics Major Product Offerings
7.6.4 Bio-Rad Laboratories Inc. Liquid Biopsy For Cancer Diagnostics Revenue in Global Market (2018-2023)
7.6.5 Bio-Rad Laboratories Inc. Key News & Latest Developments
7.7 QIAGEN Inc.
7.7.1 QIAGEN Inc. Company Summary
7.7.2 QIAGEN Inc. Business Overview
7.7.3 QIAGEN Inc. Liquid Biopsy For Cancer Diagnostics Major Product Offerings
7.7.4 QIAGEN Inc. Liquid Biopsy For Cancer Diagnostics Revenue in Global Market (2018-2023)
7.7.5 QIAGEN Inc. Key News & Latest Developments
7.8 Exact Sciences Corporation
7.8.1 Exact Sciences Corporation Company Summary
7.8.2 Exact Sciences Corporation Business Overview
7.8.3 Exact Sciences Corporation Liquid Biopsy For Cancer Diagnostics Major Product Offerings
7.8.4 Exact Sciences Corporation Liquid Biopsy For Cancer Diagnostics Revenue in Global Market (2018-2023)
7.8.5 Exact Sciences Corporation Key News & Latest Developments
7.9 Bio-Techne Corporation
7.9.1 Bio-Techne Corporation Company Summary
7.9.2 Bio-Techne Corporation Business Overview
7.9.3 Bio-Techne Corporation Liquid Biopsy For Cancer Diagnostics Major Product Offerings
7.9.4 Bio-Techne Corporation Liquid Biopsy For Cancer Diagnostics Revenue in Global Market (2018-2023)
7.9.5 Bio-Techne Corporation Key News & Latest Developments
7.10 ArcherDX Inc.
7.10.1 ArcherDX Inc. Company Summary
7.10.2 ArcherDX Inc. Business Overview
7.10.3 ArcherDX Inc. Liquid Biopsy For Cancer Diagnostics Major Product Offerings
7.10.4 ArcherDX Inc. Liquid Biopsy For Cancer Diagnostics Revenue in Global Market (2018-2023)
7.10.5 ArcherDX Inc. Key News & Latest Developments
7.11 Neogenomics Laboratories Inc.
7.11.1 Neogenomics Laboratories Inc. Company Summary
7.11.2 Neogenomics Laboratories Inc. Business Overview
7.11.3 Neogenomics Laboratories Inc. Liquid Biopsy For Cancer Diagnostics Major Product Offerings
7.11.4 Neogenomics Laboratories Inc. Liquid Biopsy For Cancer Diagnostics Revenue in Global Market (2018-2023)
7.11.5 Neogenomics Laboratories Inc. Key News & Latest Developments
7.12 Guardant Health Inc.
7.12.1 Guardant Health Inc. Company Summary
7.12.2 Guardant Health Inc. Business Overview
7.12.3 Guardant Health Inc. Liquid Biopsy For Cancer Diagnostics Major Product Offerings
7.12.4 Guardant Health Inc. Liquid Biopsy For Cancer Diagnostics Revenue in Global Market (2018-2023)
7.12.5 Guardant Health Inc. Key News & Latest Developments
7.13 Myriad Genetics Inc.
7.13.1 Myriad Genetics Inc. Company Summary
7.13.2 Myriad Genetics Inc. Business Overview
7.13.3 Myriad Genetics Inc. Liquid Biopsy For Cancer Diagnostics Major Product Offerings
7.13.4 Myriad Genetics Inc. Liquid Biopsy For Cancer Diagnostics Revenue in Global Market (2018-2023)
7.13.5 Myriad Genetics Inc. Key News & Latest Developments
7.14 Foundation Medicine Inc.
7.14.1 Foundation Medicine Inc. Company Summary
7.14.2 Foundation Medicine Inc. Business Overview
7.14.3 Foundation Medicine Inc. Liquid Biopsy For Cancer Diagnostics Major Product Offerings
7.14.4 Foundation Medicine Inc. Liquid Biopsy For Cancer Diagnostics Revenue in Global Market (2018-2023)
7.14.5 Foundation Medicine Inc. Key News & Latest Developments
7.15 Amoy Diagnostics Co. Ltd.
7.15.1 Amoy Diagnostics Co. Ltd. Company Summary
7.15.2 Amoy Diagnostics Co. Ltd. Business Overview
7.15.3 Amoy Diagnostics Co. Ltd. Liquid Biopsy For Cancer Diagnostics Major Product Offerings
7.15.4 Amoy Diagnostics Co. Ltd. Liquid Biopsy For Cancer Diagnostics Revenue in Global Market (2018-2023)
7.15.5 Amoy Diagnostics Co. Ltd. Key News & Latest Developments
7.16 Biocartis Group NV
7.16.1 Biocartis Group NV Company Summary
7.16.2 Biocartis Group NV Business Overview
7.16.3 Biocartis Group NV Liquid Biopsy For Cancer Diagnostics Major Product Offerings
7.16.4 Biocartis Group NV Liquid Biopsy For Cancer Diagnostics Revenue in Global Market (2018-2023)
7.16.5 Biocartis Group NV Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List of Tables
Table 1. Liquid Biopsy For Cancer Diagnostics Market Opportunities & Trends in Global Market
Table 2. Liquid Biopsy For Cancer Diagnostics Market Drivers in Global Market
Table 3. Liquid Biopsy For Cancer Diagnostics Market Restraints in Global Market
Table 4. Key Players of Liquid Biopsy For Cancer Diagnostics in Global Market
Table 5. Top Liquid Biopsy For Cancer Diagnostics Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Liquid Biopsy For Cancer Diagnostics Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Liquid Biopsy For Cancer Diagnostics Revenue Share by Companies, 2018-2023
Table 8. Global Companies Liquid Biopsy For Cancer Diagnostics Product Type
Table 9. List of Global Tier 1 Liquid Biopsy For Cancer Diagnostics Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Liquid Biopsy For Cancer Diagnostics Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Liquid Biopsy For Cancer Diagnostics Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Liquid Biopsy For Cancer Diagnostics Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Liquid Biopsy For Cancer Diagnostics Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application – Global Liquid Biopsy For Cancer Diagnostics Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Liquid Biopsy For Cancer Diagnostics Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Liquid Biopsy For Cancer Diagnostics Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region – Global Liquid Biopsy For Cancer Diagnostics Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Liquid Biopsy For Cancer Diagnostics Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Liquid Biopsy For Cancer Diagnostics Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Liquid Biopsy For Cancer Diagnostics Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Liquid Biopsy For Cancer Diagnostics Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Liquid Biopsy For Cancer Diagnostics Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Liquid Biopsy For Cancer Diagnostics Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Liquid Biopsy For Cancer Diagnostics Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Liquid Biopsy For Cancer Diagnostics Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Liquid Biopsy For Cancer Diagnostics Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Liquid Biopsy For Cancer Diagnostics Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Liquid Biopsy For Cancer Diagnostics Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Liquid Biopsy For Cancer Diagnostics Revenue, (US$, Mn), 2024-2029
Table 30. F. Hoffman La Roche Ltd. Company Summary
Table 31. F. Hoffman La Roche Ltd. Liquid Biopsy For Cancer Diagnostics Product Offerings
Table 32. F. Hoffman La Roche Ltd. Liquid Biopsy For Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 33. F. Hoffman La Roche Ltd. Key News & Latest Developments
Table 34. Thermo Fisher Scientific Inc. Company Summary
Table 35. Thermo Fisher Scientific Inc. Liquid Biopsy For Cancer Diagnostics Product Offerings
Table 36. Thermo Fisher Scientific Inc. Liquid Biopsy For Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 37. Thermo Fisher Scientific Inc. Key News & Latest Developments
Table 38. Agilent Technologies Inc. Company Summary
Table 39. Agilent Technologies Inc. Liquid Biopsy For Cancer Diagnostics Product Offerings
Table 40. Agilent Technologies Inc. Liquid Biopsy For Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 41. Agilent Technologies Inc. Key News & Latest Developments
Table 42. Illumina Inc. Company Summary
Table 43. Illumina Inc. Liquid Biopsy For Cancer Diagnostics Product Offerings
Table 44. Illumina Inc. Liquid Biopsy For Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 45. Illumina Inc. Key News & Latest Developments
Table 46. The Menarini Group Company Summary
Table 47. The Menarini Group Liquid Biopsy For Cancer Diagnostics Product Offerings
Table 48. The Menarini Group Liquid Biopsy For Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 49. The Menarini Group Key News & Latest Developments
Table 50. Bio-Rad Laboratories Inc. Company Summary
Table 51. Bio-Rad Laboratories Inc. Liquid Biopsy For Cancer Diagnostics Product Offerings
Table 52. Bio-Rad Laboratories Inc. Liquid Biopsy For Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 53. Bio-Rad Laboratories Inc. Key News & Latest Developments
Table 54. QIAGEN Inc. Company Summary
Table 55. QIAGEN Inc. Liquid Biopsy For Cancer Diagnostics Product Offerings
Table 56. QIAGEN Inc. Liquid Biopsy For Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 57. QIAGEN Inc. Key News & Latest Developments
Table 58. Exact Sciences Corporation Company Summary
Table 59. Exact Sciences Corporation Liquid Biopsy For Cancer Diagnostics Product Offerings
Table 60. Exact Sciences Corporation Liquid Biopsy For Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 61. Exact Sciences Corporation Key News & Latest Developments
Table 62. Bio-Techne Corporation Company Summary
Table 63. Bio-Techne Corporation Liquid Biopsy For Cancer Diagnostics Product Offerings
Table 64. Bio-Techne Corporation Liquid Biopsy For Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 65. Bio-Techne Corporation Key News & Latest Developments
Table 66. ArcherDX Inc. Company Summary
Table 67. ArcherDX Inc. Liquid Biopsy For Cancer Diagnostics Product Offerings
Table 68. ArcherDX Inc. Liquid Biopsy For Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 69. ArcherDX Inc. Key News & Latest Developments
Table 70. Neogenomics Laboratories Inc. Company Summary
Table 71. Neogenomics Laboratories Inc. Liquid Biopsy For Cancer Diagnostics Product Offerings
Table 72. Neogenomics Laboratories Inc. Liquid Biopsy For Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 73. Neogenomics Laboratories Inc. Key News & Latest Developments
Table 74. Guardant Health Inc. Company Summary
Table 75. Guardant Health Inc. Liquid Biopsy For Cancer Diagnostics Product Offerings
Table 76. Guardant Health Inc. Liquid Biopsy For Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 77. Guardant Health Inc. Key News & Latest Developments
Table 78. Myriad Genetics Inc. Company Summary
Table 79. Myriad Genetics Inc. Liquid Biopsy For Cancer Diagnostics Product Offerings
Table 80. Myriad Genetics Inc. Liquid Biopsy For Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 81. Myriad Genetics Inc. Key News & Latest Developments
Table 82. Foundation Medicine Inc. Company Summary
Table 83. Foundation Medicine Inc. Liquid Biopsy For Cancer Diagnostics Product Offerings
Table 84. Foundation Medicine Inc. Liquid Biopsy For Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 85. Foundation Medicine Inc. Key News & Latest Developments
Table 86. Amoy Diagnostics Co. Ltd. Company Summary
Table 87. Amoy Diagnostics Co. Ltd. Liquid Biopsy For Cancer Diagnostics Product Offerings
Table 88. Amoy Diagnostics Co. Ltd. Liquid Biopsy For Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 89. Amoy Diagnostics Co. Ltd. Key News & Latest Developments
Table 90. Biocartis Group NV Company Summary
Table 91. Biocartis Group NV Liquid Biopsy For Cancer Diagnostics Product Offerings
Table 92. Biocartis Group NV Liquid Biopsy For Cancer Diagnostics Revenue (US$, Mn) & (2018-2023)
Table 93. Biocartis Group NV Key News & Latest Developments
List of Figures
Figure 1. Liquid Biopsy For Cancer Diagnostics Segment by Type in 2022
Figure 2. Liquid Biopsy For Cancer Diagnostics Segment by Application in 2022
Figure 3. Global Liquid Biopsy For Cancer Diagnostics Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Liquid Biopsy For Cancer Diagnostics Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Liquid Biopsy For Cancer Diagnostics Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Liquid Biopsy For Cancer Diagnostics Revenue in 2022
Figure 8. By Type - Global Liquid Biopsy For Cancer Diagnostics Revenue Market Share, 2018-2029
Figure 9. By Application - Global Liquid Biopsy For Cancer Diagnostics Revenue Market Share, 2018-2029
Figure 10. By Type - Global Liquid Biopsy For Cancer Diagnostics Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Liquid Biopsy For Cancer Diagnostics Revenue Market Share, 2018-2029
Figure 12. By Application - Global Liquid Biopsy For Cancer Diagnostics Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Liquid Biopsy For Cancer Diagnostics Revenue Market Share, 2018-2029
Figure 14. By Region - Global Liquid Biopsy For Cancer Diagnostics Revenue Market Share, 2018-2029
Figure 15. By Country - North America Liquid Biopsy For Cancer Diagnostics Revenue Market Share, 2018-2029
Figure 16. US Liquid Biopsy For Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Liquid Biopsy For Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Liquid Biopsy For Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Liquid Biopsy For Cancer Diagnostics Revenue Market Share, 2018-2029
Figure 20. Germany Liquid Biopsy For Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 21. France Liquid Biopsy For Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Liquid Biopsy For Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Liquid Biopsy For Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Liquid Biopsy For Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Liquid Biopsy For Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Liquid Biopsy For Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Liquid Biopsy For Cancer Diagnostics Revenue Market Share, 2018-2029
Figure 28. China Liquid Biopsy For Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Liquid Biopsy For Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Liquid Biopsy For Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Liquid Biopsy For Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 32. India Liquid Biopsy For Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Liquid Biopsy For Cancer Diagnostics Revenue Market Share, 2018-2029
Figure 34. Brazil Liquid Biopsy For Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Liquid Biopsy For Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Liquid Biopsy For Cancer Diagnostics Revenue Market Share, 2018-2029
Figure 37. Turkey Liquid Biopsy For Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Liquid Biopsy For Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Liquid Biopsy For Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Liquid Biopsy For Cancer Diagnostics Revenue, (US$, Mn), 2018-2029
Figure 41. F. Hoffman La Roche Ltd. Liquid Biopsy For Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Thermo Fisher Scientific Inc. Liquid Biopsy For Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Agilent Technologies Inc. Liquid Biopsy For Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Illumina Inc. Liquid Biopsy For Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. The Menarini Group Liquid Biopsy For Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Bio-Rad Laboratories Inc. Liquid Biopsy For Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. QIAGEN Inc. Liquid Biopsy For Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Exact Sciences Corporation Liquid Biopsy For Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Bio-Techne Corporation Liquid Biopsy For Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. ArcherDX Inc. Liquid Biopsy For Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Neogenomics Laboratories Inc. Liquid Biopsy For Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. Guardant Health Inc. Liquid Biopsy For Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 53. Myriad Genetics Inc. Liquid Biopsy For Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 54. Foundation Medicine Inc. Liquid Biopsy For Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 55. Amoy Diagnostics Co. Ltd. Liquid Biopsy For Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 56. Biocartis Group NV Liquid Biopsy For Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)


※参考情報

がん診断用リキッドバイオプシーは、血液やその他の体液を用いてがんの診断や治療に関連する情報を得る手法です。この技術は、従来の組織生検や画像診断などに代わる新しいアプローチとして注目されています。リキッドバイオプシーは、特に早期発見や再発のモニタリング、治療効果の評価において重要な役割を果たす可能性があります。

リキッドバイオプシーの主な特徴は、非侵襲的であることです。従来の生検では、腫瘍組織を採取するために手術や針での穿刺が必要でした。一方、リキッドバイオプシーでは、患者の血液などを採取するだけで、がん細胞やその産物を解析することが可能です。このため、患者の負担が少なく、複数回の検査が容易であるため、がん治療の経過観察にも適しています。

リキッドバイオプシーでは、主に二つのタイプのバイオマーカーが使用されます。一つは循環腫瘍細胞（CTC）であり、もう一つは循環腫瘍DNA（ctDNA）です。CTCは、血流に存在するがん細胞であり、腫瘍の進行度や転移の有無を知る手がかりとなります。一方、ctDNAは、がん細胞から放出されたDNAの断片で、遺伝子変異やエピジェネティックな変化を検出することで、がんの特性や進行状況を評価できます。

リキッドバイオプシーの用途は多岐にわたります。例えば、がんの初期診断において、通常のスクリーニングでは発見が難しい微小な腫瘍や早期の異常を検知する手段として利用されています。また、治療の選択においても、ctDNAを分析することで、特定の治療に対する感受性や抵抗性を予測することができ、個別化医療の実現に寄与します。さらに、がん治療中のモニタリングや再発の早期発見にも役立つため、治療方針の見直しや患者の予後の改善に貢献することが期待されています。

リキッドバイオプシーの実施にあたっては、関連する技術が幾つか存在します。例えば、次世代シーケンシング（NGS）は、ctDNAの遺伝子変異を高精度で解析するための重要な技術です。この技術により、大量のDNA情報を短時間で処理できるため、がんの多様な変異を効率的に把握することが可能です。また、デジタル PCRやマイクロ流体デバイスなども、精度の高いバイオマーカー検出に寄与しています。

現在、リキッドバイオプシーは多くの研究機関や企業で開発が進められていますが、その普及に向けては、精度や信頼性の向上、コストの低減、規模の拡大が求められています。また、倫理的な問題や法的な整備も重要な課題です。特に、リキッドバイオプシーによって得られる情報がどのように扱われるのか、患者のプライバシーがどのように保護されるのかが、多くの関係者にとって関心の高いポイントとなっています。

今後の展望として、リキッドバイオプシーはさらなる進化を遂げると考えられます。新たな検出技術の開発や、バイオマーカーの標準化が進むことで、より高い精度でのがん検査が可能となるでしょう。また、人工知能や機械学習の技術を活用することで、大規模なデータ分析が実現し、診断の迅速化や個別化医療の進展が期待されます。

リキッドバイオプシーは、がん診断においてまさに革命的な技術であり、多くの患者さんに新たな治療の選択肢を提供することができる可能性を秘めています。従来の方法では得られなかった情報を提供することで、がん治療における新しい時代を切り開く役割を果たすことが期待されます。さらなる研究と発展が望まれる分野であり、今後も注目が集まることでしょう。


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 乱用薬物診断キットのグローバル市場2023：尿検査、唾液検査、血液検査
  • 乱用薬物用診断キットの世界市場2023-2029：尿検査、唾液検査、血液検査
  • 乱用薬物検査用試薬の世界市場2025-2031：尿検査、唾液検査、血液検査、毛髪・汗検査、その他
  • 乱用薬物検査用試薬キットの世界市場2025-2031：尿検査、唾液検査、血液検査、毛髪・汗検査、その他
  • 乱用薬物検査装置の世界市場2025-2031：尿検査、唾液検査、血液検査、毛髪・汗検査、その他
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(MMG23DC12386 )"がん診断用リキッドバイオプシーのグローバル市場展望 2023年-2029年：血液検査、尿検査、唾液検査" (英文：Liquid Biopsy For Cancer Diagnostics Market, Global Outlook and Forecast 2023-2029)はMarket Monitor Global社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。